Managing Respiratory Illness

Managing asthma, EIB, and COPD: Professional guidelines

Managing asthma

Guidelines for the diagnosis and management of asthma are available from the National Heart, Lung, and Blood Institute (NHLBI). A few of the key recommendations are summarized below.

Asthma Diagnosis
  • Determine if episodes of airway obstruction are present using medical history and a physical exam.1
  • In patients 5 years of age or older, determine if the airway obstruction is reversible using spirometry before and after using a short-acting beta2-agonist (SABA) like ProAir® HFA.1
Asthma Treatment
  • Develop a written asthma action plan.
  • SABAs like ProAir® HFA are a treatment of choice for relief of acute symptoms.1
  • Patients who have symptoms more than twice a week during the day or who use more than one canister (200 puffs) per month may require a long-term control medication.1

Managing exercise-induced bronchospasm (EIB)

Recommendations for the management of EIB are also included in the NHLBI’s guidelines for the diagnosis and management of asthma. Key points include:
  • Pretreat before exercise—SABAs are the treatment of choice for prevention of EIB.1
  • Encourage patients to warm up before exercise and to cover their mouths with a mask or scarf in cold weather.1
  • EIB symptoms may be the result of poorly controlled persistent asthma. Consider long-term control therapy.1

Managing chronic obstructive pulmonary disease (COPD)

Guidelines for the diagnosis, management, and prevention of COPD are available from the Global Initiative for Chronic Obstructive Lung Disease (GOLD). A few of the key recommendations are summarized below.

COPD Diagnosis
  • Consider COPD in patients with dyspnea, chronic cough or sputum production and a history of exposure to the following:2
    • Tobacco smoke2
    • Occupational dust and chemicals2
    • Smoke from home cooking and heating fuels2
  • Confirm diagnosis by spirometry.2
COPD Treatment
  • Encourage current smokers to quit.2
  • Bronchodilator medications, including SABAs, are central to the symptomatic management of COPD.2
  • Consider influenza and pneumonia vaccination.2
  • Encourage patients to try exercise training programs, which can improve exercise tolerance and reduce symptoms of dyspnea and fatigue.2
References
  1. NHLBI Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Accessed April 20, 2010.
  2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2009.
ProAir® HFA (albuterol sulfate) Inhalation Aerosol is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Important Safety Information

  • Inhaled albuterol sulfate can produce paradoxical bronchospasm that may be life-threatening. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister.
  • Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma.
  • ProAir HFA, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), convulsive disorders, hyperthyroidism, and diabetes.
  • Potential drug interactions can occur with beta-blockers, diuretics, digoxin, or monoamine oxidase inhibitors, and tricyclic antidepressants.
  • Do not exceed the recommended dose.
  • Adverse events, which occurred at an incidence rate of at least 3% with ProAir HFA, include headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis.
©2011 Teva Respiratory, LLC. This site is intended for U.S. residents only. All Rights Reserved.
ProAir® HFA is a registered trademark of Teva Respiratory, LLC.
EIB Active™ is a trademark of Teva Respiratory, LLC. EIB Active™ is sponsored by Teva Respiratory.

101448